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Abstract: Introduction: Prolonged drug delivery in the oral cavity offers many 
advantages, such as reducing adverse effects. Pilocarpine is an FDA-approved 
parasympathomimetic drug for the treatment of glandular hypofunction; howe-
ver, its adverse effects limit its use. Objective: To evaluate the stimulation of 
salivary flow by the use of pilocarpine-releasing films, as well as their effects on 
the symptoms of xerostomia and adverse effects in patients with Sjögren’s syn-
drome (SS). Materials and methods:  Hy droxypropylmethylcellulose (Methocel 
K4MCR) films were prepared in 1% acetic acid and pilocarpine was added un-
der magnetic stirring. The pH and thickness, as well as diffusion uniformity and 
kinetics of drug release per cm2 were evaluated by spectrophotometry. The films 
were tested sublingually in 40 patients with Sjögren’s syndrome for a period of 
two weeks. Changes in their salivary flow were evaluated by analyzing samples 
of total saliva. Additionally, patients were screened for symptoms of xerostomia 
and adverse effects. Results: The films had a pH of 2.91±0.035, a thickness of 
0.06866±0.00152μm, and a diffusion uniformity of 91% per cm2. Use of the 
films resulted in an increase in salivary flow in both primary and secondary Sjö-
gren’s syndrome, but this increase was only significant in primary SS.  Conclu-
sion: Films showed optimal physicochemical properties for their administration, 
and proved effective in stimulating salivary flow without causing adverse effects 
during their administration.
Keywords: hyposalivation, Sjögren’s syndrome, pilocarpine, hydroxypropylme-
thylcellulose, xerostomia.
INTRODUCTION.
Sjögren’s syndrome is a slow progressive chronic autoimmune disease of 
unknown etiology,1 with a prevalence of 0.1-3.0% at global scale.2
SS may occur as primary3 or secondary SS in conjunction with other 
autoimmune diseases such as rheumatoid arthritis4 and systemic lupus 
erythematosus.5 Prevalence of SS has been estimated at 300 to 600 per 
100,000 people,6 being more frequent in adults in their fourth or fifth 
decade of life, with a female/male ratio of 9:1.7
Sialogogue drugs, such as pilocarpine, have a wide range of adverse 
effects.8 Alternative ways to administer these type of medicines have been 
sought in order to reduce their adverse effects, such as mouthwashes, 
spray,10 gel,11 tablets/pills12 and polymeric inserts.13
Local use of prolonged drug administration or delivery provides multiple 
advantages, such as increased pharmacological action at the desired site, 
reduction of drug dose and mitigation of adverse effects.14 In previous 
research it has been demonstrated that the local use of bioadhesive films 
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containing pilocarpine is effective for increasing the salivary 
flow in vivo.15 They have also proved to be biocompatible 
and possess the best physicochemical properties for this 
type their administration.16
The objective of this study was to evaluate the 
stimulation of salivary flow by the use of pilocarpine-
releasing films, as well as their effects on the symptoms 
of xerostomia and adverse effects in patients with 
Sjögren’s syndrome.
MATERIALS AND METHODS.
Design and population.
A cohort study, involving a 2-week follow-up period, 
was carried out. Evaluation was performed by a single 
examiner. Study subjects included patients with SS pre-
viously diagnosed by the Rheumatology Unit at Hos-
pital Universitario at Universidad Autónoma de Nuevo 
León, Mexico.
Male and female patients with primary and secon-
dary SS, aged 40 to 80 years old, were included in 
the study. Patients were excluded from the study who 
presented with another factor inducing hyposalivation 
that may have affected the outcome, such as: head and 
neck radiation therapy, history of Hepatitis C, Human 
Immunodeficiency Virus (HIV), pre-existing lympho-
ma, sarcoidosis, subjects with graft-versus-host disease, 
diabetes mellitus, and patients with a history of anti-
cholinergic and parasympathomimetics drug use in the 
previous 4 months. 
Patients who did not attend the follow-up appoint-
ments, who did not follow the treatment rigorously, 
those who stopped treatment during the time of experi-
mentation and patients who developed any disease du-
ring the course of the study or ingested drugs that may 
have produced any changes in salivation were excluded 
from the study.
Sample size estimation considered a prevalence of 
35%, an error of 14% and a confidence level of 95%. 
Ten patients were estimated for each group, resulting in 
a total of 40 patients.
Preparation of films
Hydroxypropylmethylcellulose (HPMC, Methocel 
K4M CR), donated by the company Colorcon from 
Mexico (Cuajimalpa, Mexico) and pilocarpine obtained 
from Sigma-Aldrich Chemical Company (USA) were 
used to carry out the experimental studies.
In an aqueous solution containing 1% acetic acid, a 
formulation of HPMC (1.5g/100ml), 0.5mL/100mL 
of glycerin, was prepared adding a dose of pilocarpine 
(2.5mg/mL). The formulation was homogenized under 
magnetic stirring at 70ºC for one hour. Afterwards, it 
was aliquoted into 15ml Petri dishes and air-dried for 24 
hours, at which stage it was ready to use.
Evaluation of physicochemical properties of films
During the preparation of films, once the homogeniza-
tion process was finished and the formulation cooled to 
room temperature, pH was recorded using a pH meter (Ul-
traBASIC, Denver Instrument, USA).
After the films were dried and removed from the Petri 
dishes, their thickness was determined by means of a mi-
crometer in five different zones, as described previously.16
To determine the uniformity of pilocarpine in the 
films, 2.5mg of pilocarpine were dissolved in 25mL of 
distilled water under magnetic stirring at 37ºC for one 
hour, and absorbance was measured using a spectropho-
tometer (Genesys 10uv Scanning, ThermoFisher, USA) 
in a range of different wave lengths (200nm-500nm) at 
intervals of 10nm, in order to obtain a reference value 
that could be used as control, and the wave length at 
which the highest absorbance value was recorded was 
chosen as reference.
Once the reference value for the control with pilocarpi-
ne was obtained, 1cm2 of the HPMC/pilocarpine film was 
taken and dissolved in 25mL of distilled water at 37ºC 
under magnetic stirring for one hour, the absorbance 
of the solution was measured in order to determine the 
quantity of pilocarpine contained in the films.
To determine the drug release time of the HPMC/Pi-
locarpine film, 1cm2 of the film was placed in 25mL of 
distilled water at 37ºC under magnetic stirring. Additio-
nally, in order to assess release kinetics, the optical den-
sity of the solution was measured every 15 minutes, over 
a period of 12 hours at 280nm, which was determined 
during the drug diffusion uniformity test as optimal.
Evaluation of salivary flow
In order to evaluate changes in the salivary flow pro-
duced by the films, the salivary flow rate was obtained 
by collecting a sample of total saliva from the patients. 
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During this procedure patients were instructed to remain 
seated and completely at rest, without moving facial mus-
cles, the tongue or swallowing saliva for 5 minutes. Subse-
quently, the collected saliva was emptied into pre-weighed 
plastic microtubes.
After obtaining the samples, microtubes were weighed 
again. The total weight obtained minus the initial weight 
of the tube was calculated in order to obtain the rate of 
salivary volume in a period of 5 minutes. Then, this value 
was divided by 5 with the aim of finding the volume of 
saliva produced per minute. This procedure was performed 
before and after the placement of the films.
Application of films
Patients were given a brochure with information about 
the study and its benefits. In addition, a kit was provided 
for each patient. The kit included two boxes containing 
the films (previously sterilized with UV light), sterile 
tweezers and an instruction manual explaining how to 
place the films. The manual included a section for consi-
derations and frequently asked questions.
The films were placed sublingually every 12 hours (9 am 
and 9 pm) for two weeks. For this, patients had to use the 
included sterile tweezers. Once the film was adhered to the 
mucosa, the patient was able to perform any subsequent ac-
tivity, except smoking and drinking alcohol.
Evaluation of xerostomia and adverse effects
The evaluation of xerostomia consisted of a symptomato-
logy survey and a clinical evaluation. The questionnaire was 
applied before and after the treatment, and included ques-
tions regarding difficulty speaking, difficulty swallowing 
solid or dry foods, dysgeusia, dry lips and throat, a burning 
sensation on the tongue, mouth breathing, dry eyes and the 
frequent need for drinking fluids.  To answer these ques-
tions, the patient had three options: “No”, “Often” or “A 
few times”.
Clinical evaluation consisted of three aspects; each of 
them was given a value to determine the degree of dry-
ness. The first aspect was lip dryness where: 0=Normal, 
1=Dryness of the vermilion zone and 2=Presence of angular 
cheilitis. The second aspect was the dryness of the mucous 
membranes where: 0=Normal, 1=Dry without causing the 
tongue depressor to stick, 2=Very dry causing the tongue 
depressor to stick; and 3=Very dry causing the tongue de-
pressor to stick and without detecting parotid ducts.
At the end of treatment, a survey was conducted on 
the presence of adverse effects, questioning patients about 
anxiety symptoms, excessive sweating, nausea or vomiting, 
gastritis or heartburn, palpitations, difficulty breathing, 
increased urinary frequency, spontaneous tearing eyes, as 
well as their experience with the films.
Ethical Considerations
This study was approved by the Bioethics Committee 
of Universidad Autónoma de Nuevo León (SPSI - 010613. 
Folio: 0094). Before enrollment and reviewing of medical 
history, each patient signed an informed consent form.
Data analysis
Results were analyzed by means of ANOVA and Tukey 
HSD tests to identify specific groups that showed significant 
results among them, both with 95% reliability (IBM SPSS 
Statistics, Version 20, USA and Microsoft Excel 2010).
RESULTS.
Results showed that the formulation of the films had 
a mean pH of 2.91±0.035. The thickness of the films was 
measured in five different zones to obtain a uniform mean 
thickness of 0.06866±0.00152μm.
The mean optical density of pilocarpine dissolved in 
25mL of distilled water at 280nm was 0.034±0.00057. 
Subsequently, absorbance of film was performed under 
the same conditions, obtaining 0.031±0.00058, resulting 
in a uniformity of 91% per cm2.
During release kinetics relative to the uniformity of 
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  Primary Sjögren        Control Secondary Sjögren Control
   Mean SD Mean SD  Mean SD Mean SD
Initial 0.170* 0.246 0.359 0.416 0.153 0.255 0.161 0.167
Week 2 0.298* 0.333 0.376 0.436 0.224 0.320 0.154 0.163
p-value                    0.047                                         0.053                                             0.135                                       0.057
Table 1. Initial and final sialometry.
*SD= Standard Deviation.
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 Primary Sjögren  Control Secondary Sjögren  Control
Item  No      Often   Few No      Often   Few No Often   Few  No  Often Few  
   times   times   times   times
Did experience anxiety and/or tremors? 100% 0.0% 0.0%       83.3% 0.0% 16.7% 87.5% 12.5% 0.0% 100% 0.0% 0.0%
Did you experience increased sweating? 90.0% 0.0% 10.0% 100% 0.0% 0.0% 75.0% 12.5% 12.5% 100% 0.0% 0.0%
Did you feel nauseous or vomited? 90.0% 10.0% 0.0% 100% 0.0% 0.0% 87.5% 0.0% 12.5% 100% 0.0% 0.0%
Did you experience gastritis or heartburn? 80.0% 0.0% 20.0% 100% 0.0% 0.0% 87.5% 0.0% 12.5% 100% 0.0% 0.0%
Did you experience palpitations or increased heart rate? 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0%
Have you had difficulty breathing? 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0%
Did you notice an increase in urinary frequency? 80.0% 10.0% 10.0% 83.3% 0.0% 16.7% 87.5% 0.0% 12.5% 100% 0.0% 0.0%
Did you have a tearing eye? 60.0% 0.0% 40.0% 100% 0.0% 0.0% 100% 0.0% 0.0% 75.0% 0.0% 25.0%
Do you think the administration of films alleviated 0.0% 40.0% 60.0% 33.3% 16.7% 50.0% 25.0% 37.5% 37.5% 0.0% 0.0% 100.0%
the dryness in your mouth?
Did you suffer from irritation or feel any discomfort 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0%
in the oral mucosa because of the films? 
 Primary Sjögren  Control Secondary  Sjögren  Control
  No    Often   Few  No        Often  Few  No   Often Few   No   Often  Few
Item    time   time    time   time
Initial
Do you experience difficulty speaking due to dry mouth? 50% 20% 30% 33% 50% 17% 25% 50% 25% 38% 13% 50%
Do you have difficulty swallowing solid or dry food? 20% 40% 40% 17% 33% 50% 38% 50% 13% 38% 0% 63%
Do you think your meals have no taste? 60% 0% 40% 33% 17% 50% 38% 38% 25% 50% 50% 0%
Do you feel a burning sensation on your tongue? 60% 20% 20% 33% 50% 17% 38% 25% 38% 50% 13% 38%
Do you feel your lips dry? 40% 30% 30% 0% 83% 17% 13% 75% 13% 50% 13% 38%
Have you had swollen salivary glands in adulthood? 70% 20% 10% 67% 17% 17% 63% 25% 13% 100% 0% 0%
Do you need to get up during the night to drink fluids 70% 10% 20% 17% 0% 83% 63% 0% 38% 50% 0% 50%
Do you usually breathe through your mouth? 60% 10% 30% 67% 0% 33% 38% 25% 38% 13% 38% 50%
Do you feel your eyes dry? 0% 80% 20% 0% 83% 17% 13% 63% 25% 0% 13% 88%
Do you feel dryness in your throat? 30% 50% 20% 0% 83% 17% 38% 63% 0% 0% 88% 13%
week 2 
Do you experience difficulty speaking due to dry mouth? 80% 0.0% 20% 83.3% 0.0% 16.7% 50 % 0% 50% 100% 0% 0%
Do you have difficulty swallowing solid or dry food? 60% 0% 40% 83.3% 16.7% 0% 25% 25% 50% 62.5% 37.5% 0.0%
Do you think your meals have no taste? 80.0% 0% 20.0% 83.3% 0% 16.7% 75% 12.5% 12.5% 50% 12.5% 37.5%
Do you feel a burning sensation on your tongue? 100% 0% 0.0% 66.7% 0% 33.3% 100% 0.0% 0.0% 87.5% 0.0% 12.5%
Do you feel your lips dry? 40.0% 20.0% 40.0% 33.3% 33.3% 33.3% 62.5% 12.5% 25.0% 12.5% 0.0% 87.5%
Have you had swollen salivary glands in adulthood? 90.0% 0.0% 10.0% 100% 0.0% 0.0% 87.5% 12.5% 0.0% 50.0% 37.5% 12.5%
Do you need to get up during the night to drink fluids 80.0% 0.0% 20.0% 100% 0.0% 0.0% 87.5% 0.0% 12.5% 75.0% 0.0% 25.0%
Do you usually breathe through your mouth? 80.0% 0.0% 20.0% 50.0% 0.0% 50.0% 62.5% 25.0% 12.5% 50.0% 25.0% 25.0%
Do you feel your eyes dry? 10.0% 30.0% 60.0% 50.0% 33.3% 16.7% 37.5% 37.5% 25.0% 25.0% 62.5% 12.5%
Do you feel dryness in your throat? 50.0% 10.0% 40.0% 83.3% 16.7% 0.0% 37.5% 37.5% 25.0% 25.0% 62.5% 12.5%
      Primary Sjögren        Control            Secondary Sjögren             Control
Item 0 1 2 0 1 2 0 1 2 0 1 2
Initial 
Dryness of lips 50.0% 50.0% 0.0% 0.0% 100% 0.0% 12.5% 75.0% 12.5% 12.5% 87.5% 0.0%
Dryness of the mucosa 10.0% 70.0% 20.0% 16.7% 66.7% 16.7% 0.0% 100% 0.0% 12.5% 87.5% 0.0%
Palpation of the major salivary glands 90.0% 10.0% 0.0% 83.3% 16.7% 0.0% 75.0% 25.0% 0.0% 100% 0.0% 0.0%
Weeek 2 
Dryness of lips 50.0% 50.0% 0.0% 0.0% 100% 0.0% 12.5% 87.5% 0.0% 12.5% 87.5% 0.0%
Dryness of the mucosa 70.0% 30.0% 0.0% 0.0% 100% 0.0% 12.5% 87.5% 0.0% 12.5% 87.5% 0.0%
Palpation of the major salivary glands 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0% 100% 0.0% 0.0%
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Table 4. Evaluation of treatment with pilocarpine.
Table 2. Evaluation of symptomatology of initial and final xerostomia.
Table 3. Initial and final clinical evaluation.
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the drug, it was observed that the release rate was 55% at 
30min, 88% at 1h, 91% at 1h 30min, 97% at 2h and 2h 
30m and 100% from 3 to 4h.
The results of the evaluation of the salivary flow be-
fore and after the treatment are shown in Table 1, symp-
tomatology in Table 2, clinical xerostomia in Table 3 
and adverse effects in Table 4.
DISCUSSION.
Due to the wide variety of adverse effects of sialogo-
gue drugs, alternative ways to administer this type of 
medicines have been sought in order to mitigate their ad-
verse effects. The local use of prolonged delivery of drugs 
through films provides multiple advantages, increasing 
the pharmacological action at the desired site, reducing 
the dose used and mitigating adverse effects, in addition 
to avoiding hepatic metabolism, gastric irritation and 
enzymatic degradation by the gastrointestinal environ-
ment.17 In vivo and in vitro oral administration methods 
based on chitosan and HPMC have been recently devel-
oped for the prolonged release of drugs such as pilocar-
pine, becoming a promising means for controlled delivery 
method in the oral cavity.15
Lockhart et al. pioneered studies on the controlled re-
lease of pilocarpine. They proposed the administration 
of three doses of 15mg of pilocarpine hydrochloride at 
12 hour intervals. The formulation was designed to re-
lease 5mg for the first 2 hours, 11mg for the next 8 hours 
and the remaining drug for the next 4 to 6 hours. The 
initial salivary flow rate of 0.6mL/min was increased to 
1.25mL/min during the first hour of initial adminis-
tration, and at 4 hours the salivary flow was double the 
initial measurement, then declining to 1.14mL/min at 
10 hours. Likewise, the first dose of the second admin-
istration increased the salivary flow to 1.28mL/min and 
the third dose to 1.37mL/min during the first two hours, 
however, although this result was satisfactory, its appli-
cation was not an intrabuccal local application.18
Gibson et al. evaluated the controlled release of pilo-
carpine by intrabuccal polymer inserts in patients with 
Sjögren’s syndrome. They designed a polymer hydrogel 
buccal insert 17x5mm in size and 0.6mm thick, containing 
5mg of pilocarpine hydrochloride, which should be placed 
3 times a day and changed every 3 hours. Their results sug-
gest that there is a marked improvement in salivary flow 
rate from day 8 of treatment, with an increase from 0 to 
1.2mL, maintaining that high salivary flow rate for 4 days. 
However, although their study found excellent salivary flow 
rates, it was only conducted on seven patients; researchers 
did not describe the formulation used or the methods of 
verifying the uniformity of the drug in the polymer insert. 
Nevertheless their findings coincide with the present study 
in finding a stimulation of salivary flow in primary SS.13
Previous studies have evaluated the physicochemical, an-
timicrobial, cytotoxic and sialogogue properties; the results 
showed that films have the best physicochemical properties 
for their mode of administration, a high cell viability, pro-
duce considerably increased salivary flow, but do not show 
antimicrobial activity.16
CONCLUSION.
Films showed optimal physicochemical properties for 
their manipulation and administration, with the total re-
lease of the drug after 3h in an aqueous medium. They 
also proved effective in stimulating salivary flow in pri-
mary and secondary SS, without causing adverse effects.
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